Common name
N-methylpyrazine-2-carboxamide
IUPAC name
N-methylpyrazine-2-carboxamide
SMILES
C(=O)(NC)c1nccnc1
Common name
N-methylpyrazine-2-carboxamide
IUPAC name
N-methylpyrazine-2-carboxamide
SMILES
C(=O)(NC)c1nccnc1
INCHI
InChI=1S/C6H7N3O/c1-7-6(10)5-4-8-2-3-9-5/h2-4H,1H3,(H,7,10)
FORMULA
C6H7N3O
Common name
N-methylpyrazine-2-carboxamide
IUPAC name
N-methylpyrazine-2-carboxamide
Molecular weight
137.139
clogP
0.402
clogS
-1.556
Frequency
0.0007
HBond Acceptor
3
HBond Donor
1
Total PolarSurface Area
54.88
Number of Rings
1
Rotatable Bond
1
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00077 | Bortezomib |
|
Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies. |
| FDBD01369 | Telaprevir |
|
Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; CYP3A4 Inhibitors; | Treating chronic hepatitis C virus (genotype 1) infection in patients with compensated liver (due to liver diseases like cirrhosis) that are treatment naive or have failed therapy with interferons (either null or partial responders and treatment relapsers). |
2 ,
1
